Alpelisib demonstrates tolerable safety and favorable clinical efficiency in patients with PIK3CA-altered, HR-positive, HER2-negative breast cancer in combination with fulvestrant [255, 258–260] or letrozole [261] (Fig. 3l). The gene discussed is PIK3CA; the disease is breast cancer.